Pirtobrutinib Patent Expiration
Pirtobrutinib is Used for treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy including a BTK inhibitor and a BCL-2 inhibitor. It was first introduced by Loxo Oncology Inc
Pirtobrutinib Patents
Given below is the list of patents protecting Pirtobrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Jaypirca | US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | Sep 14, 2041 | Loxo Oncol |
| Jaypirca | US12268666 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | Jul 29, 2039 | Loxo Oncol |
| Jaypirca | US10342780 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10464905 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10695323 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US10918622 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
| Jaypirca | US12220401 | Compounds useful as kinase inhibitors | Dec 16, 2036 | Loxo Oncol |
Pirtobrutinib's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Pirtobrutinib:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
